US biotech Cytokinetics (Nasdaq: CYTK) is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function.
The company’s research is focused on modulating proteins in the sarcomere, the fundamental unit of muscle contraction found within muscle cells.
These proteins are seen as key to unlocking the potential treatment of diseases caused by impaired muscle function.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze